Uterine leiomyoma: Available medical treatments and new possible therapeutic options

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 3, 2013, Pages 921-934

  Islam, Md Soriful ^a,b   Protic, Olga ^a   Giannubilo, Stefano Raffaele ^a   Toti, Paolo ^c   Tranquilli, Andrea Luigi ^a   Petraglia, Felice ^c   Castellucci, Mario ^a   Ciarmela, Pasquapina ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF RAJSHAHI   (Bangladesh)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANGIOPEPTIN; ASOPRISNIL; CABERGOLINE; CHEMOKINE; CIGLITAZONE; CURCUMIN; CYTOKINE; DANAZOL; EPIGALLOCATECHIN GALLATE; ESTROGEN; GESTRINONE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GROWTH FACTOR; HALOFUGINONE; HEPARIN; ISOLIQUIRITIGENIN; LEUPRORELIN; LEVONORGESTREL; MIFEPRISTONE; PIRFENIDONE; PLACEBO; PROGESTERONE; RALOXIFENE; ROSIGLITAZONE; TRANILAST; ULIPRISTAL; UNINDEXED DRUG; VITAMIN D;

BONE DENSITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; EPIGENETICS; EXTRACELLULAR MATRIX; HEREDITY; HOT FLUSH; HUMAN; HYPOESTROGENISM; INTRAUTERINE CONTRACEPTIVE DEVICE; MENSTRUATION; MYOMECTOMY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TUMOR GROWTH; UTERUS MYOMA; VAGINITIS;

CONTRACEPTIVE AGENTS, FEMALE; ENZYME INHIBITORS; FEMALE; HORMONE ANTAGONISTS; HORMONES; HUMANS; LEIOMYOMA; UTERINE NEOPLASMS;

EID: 84874835388     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3237     Document Type: Review

References (166)

1. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol. 1990;94:435-438. (Pubitemid 20316570)
2. Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981;36:433-445. (Pubitemid 11027013)
3. Stewart EA. Uterine fibroids. Lancet. 2001;357:293-298. (Pubitemid 32120866)
4. Al-Nafussi A. Uterine smooth-muscle tumours: practical approach to diagnosis. Curr Diagn Pathol. 2004;10:140-156. (Pubitemid 38520433)
5. Toledo G, Oliva E. Smooth muscle tumors of the uterus: a practical approach. Arch Pathol Lab Med. 2008;132:595-605. (Pubitemid 351489613)
6. Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and treatment. Am Fam Physician. 2007;75:1503-1508. (Pubitemid 46790333)
7. Marsh EE, Bulun SE. Steroid hormones and leiomyomas. Obstet Gynecol Clin North Am. 2006;33:59-67.
8. Flynn M, Jamison M, Datta S, Myers E. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol. 2006;195:955-964. (Pubitemid 44415640)
9. Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol. 1991;77:720.
10. Leather AT, Studd JW, Watson NR, Holland EF. The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy. Obstet Gynecol. 1993;81:104-107. (Pubitemid 23041712)
11. Palomba S, Orio F, Morelli M, et al. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. J Clin Endocrinol Metab. 2002;87:4476-4481. (Pubitemid 35247028)
12. Palomba S, Affinito P, Di Carlo C, Bifulco G, Nappi C. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles. Fertil Steril. 1999;72:889-895. (Pubitemid 29505455)
13. Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2010;112:126-130.
14. Wildemeersch D, Schacht E. The effect on menstrual blood loss in women with uterine fibroids of a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2002;102:74-79. (Pubitemid 34224081)
15. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90:967-973. (Pubitemid 27510139)
16. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308:1589-1592. (Pubitemid 40807499)
17. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003;111: 1037-1054. (Pubitemid 36826884)
18. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22:571-588. (Pubitemid 351804127)
19. Chegini N. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med. 2010;28:180-203.
20. Sozen I, Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet Gynecol Clin North Am. 2006;33:41-58.
21. Ciarmela P, Islam MS, Reis FM, et al. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update. 2011;17:772-790.
22. Luo X, Chegini N. The expression and potential regulatory function of micro RNAs in the pathogenesis of leiomyoma. Semin Reprod Med. 2008;26:500-514.
23. Cha PC, Takahashi A, Hosono N, et al. Agenome-wide association study identifies three loci associated with susceptibility to uterine fibroids. Nat Genet. 2011;43:447-450.
24. Marsh EE, Lin Z, Yin P, Milad M, Chakravarti D, Bulun SE. Differential expression of micro RNA species in human uterine leiomyoma versus normal myometrium. Fertil Steril. 2008;89:1771-1776. (Pubitemid 351749629)
25. Navarro A, Yin P, Monsivais D, et al. Genome-wide DNA methylation indicates silencing of tumor suppressor genes in uterine leiomyoma. PloS One. 2012;7:e33284.
26. Kiechle-Schwarz M, Sreekantaiah C, Berger CS, et al. Nonrandom cytogenetic changes in leiomyomas of the female genitourinary tract. Areport of 35 cases. Cancer Genet Cytogenet. 1991;53:125-136.
27. Rein MS, Friedman AJ, Barbieri RL, Pavelka K, Fletcher JA, Morton CC. Cytogenetic abnormalities in uterine leiomyomata. Obstet Gynecol. 1991;77:923-926.
28. Meloni AM, Surti U, Contento AM, Davare J, Sandberg AA. Uterine leiomyomas: cytogenetic and histologic profile. Obstet Gynecol. 1992;80:209-217.
29. Ligon AH, Scott IC, Takahara K, Greenspan DS, Morton CC. PCOLCE deletion and expression analyses in uterine leiomyomata. Cancer Genet Cytogenet. 2002;137:133-137. (Pubitemid 35266859)
30. Ptacek T, Song C, Walker CL, Sell SM. Physical mapping of distinct 7q22 deletions in uterine leiomyoma and analysis of a recently annotated 7q22 candidate gene. Cancer Genet Cytogenet. 2007;174:116-120. (Pubitemid 46602533)
31. Velagaleti GV, Tonk VS, Hakim NM, et al. Fusion of HMGA2 to COG5 in uterine leiomyoma. Cancer Genet Cytogenet. 2011;202: 11-16.
32. Mäkinen N, Mehine M, Tolvanen J, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334:252-255.
33. Nezhad MH, Drieschner N, Helms S, et al. 6p21 rearrangements in uterine leiomyomas targeting HMGA1. Cancer Genet Cytogenet. 2010;203:247-252.
34. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyoma. Cancer Genet Cytogenet. 2005;158:1-26. (Pubitemid 40354320)
35. El-Gharib MN, Elsobky ES. Cytogenetic aberrations and the development of uterine leiomyomata. J Obstet Gynaecol Res. 2010;36:101-107.
36. Wei LH, Torng PL, Hsiao SM, Jeng YM, Chen MW, Chen CA. Histone deacetylase 6 regulates estrogen receptor α in uterine leiomyoma. Reprod Sci. 2011;18:755-762.
37. Wang T, Zhang X, Obijuru L, et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer. 2007;46:336-347. (Pubitemid 46411325)
38. Pan Q, Luo X, Chegini N. Differential expression of micro RNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med. 2008;12:227-240. (Pubitemid 351430465)
39. Liu J, Matsuo H, Xu Q, Chen W, Wang J, Maruo T. Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro. Hum Reprod. 2007;22:1253-1259. (Pubitemid 47062792)
40. Georgieva B, Milev I, Minkov I, Dimitrova I, Bradford AP, Baev V. Characterization of the uterine leiomyoma micro RNAome by deep sequencing. Genomics. 2012;93:275-281.
41. Chuang TD, Panda H, Luo X, Chegini N. miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5. Endocr Relat Cancer. 2012;19:541-556.
42. Chuang TD, Luo X, Panda H, Chegini N. miR-93/106b and their host gene, MCM7, are differentially expressed in leiomyomas and functionally target F3 and IL-8. Mol Endocrinol. 2012;26:1028-1042.
43. Ciarmela P, Bloise E, Gray PC, et al. Activin-A and myostatin response and steroid regulation in human myometrium: disruption of their signalling in uterine fibroid. J Clin Endocrinol Metab. 2011;96:755-765.
44. Sozen I, Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril. 2002;78:1-12. (Pubitemid 34722662)
45. Ciarmela P, Wiater E, Vale W. Activin-A in myometrium: characterization of the actions on myometrial cells. Endocrinology. 2008;149:2506-2516. (Pubitemid 351574535)
46. Ciarmela P, Wiater E, Smith SM, Vale W. Presence, actions, and regulation of myostatin in rat uterus and myometrial cells. Endocrinology. 2009;150:906-914.
47. Hatthachote P, Gillespie JI. Complex interactions between sex steroids and cytokines in the human pregnant myometrium: evidence for an autocrine signaling system at term. Endocrinology. 1999;140:2533-2540. (Pubitemid 32245130)
48. Litovkin KV, Domenyuk VP, Bubnov VV, Zaporozhan VN. Interleukin-6-174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study. Exp Oncol. 2007;29:295-298. (Pubitemid 351236319)
49. Luo X, Ding L, Xu J, Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-β. Endocrinology. 2005;146:1097-1118. (Pubitemid 40289299)
50. Ding L, Xu J, Luo X, Chegini N. Gonadotropin releasing hormone and transforming growth factor β activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab. 2004;89:5549-5557. (Pubitemid 39518439)
51. Kurachi O, Matsuo H, Samoto T, Maruo T. Tumor necrosis factor-α expression in human uterine leiomyoma and its down-regulation by progesterone. J Clin Endocrinol Metab. 2001;86:2275-2280. (Pubitemid 32472952)
52. Syssoev KA, Kulagina NV, Chukhlovin AB, Morozova EB, Totolian AA. Expression of mRNA for chemokines and chemokine receptors in tissues of the myometrium and uterine leiomyoma. Bull Exp Biol Med. 2008;145:84-89.
53. Sozen I, Olive DL, Arici A. Expression and hormonal regulation of monocyte chemotactic protein-1 in myometrium and leiomyomata. Fertil Steril. 1998;69:1095-1102. (Pubitemid 28274900)
54. Wolańska M, Sobolewski K, Drozdzewicz M, Bańkowski E. Extracellular matrix components in uterine leiomyoma and their alteration during the tumour growth. Mol Cell Biochem. 1998;189: 145-152. (Pubitemid 28556559)
55. Arici A, Sozen I. Transforming growth factor-β3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril. 2000;73:1006-1011. (Pubitemid 30227527)
56. Norian JM, Malik M, Parker CY, et al. Transforming growth factor β3 regulates the versican variants in the extracellular matrixrich uterine leiomyomas. Reprod Sci. 2009;16:1153-1164.
57. Malik M, Norian J, McCarthy-Keith D, Britten J, Catherino WH. Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin Reprod Med. 2010;28:169-179.
58. Ono M, Maruyama T, Masuda H, et al. Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc Natl Acad Sci USA. 2007;104:18700-18705. (Pubitemid 350210760)
59. Ono M, Qiang W, Serna VA, et al. Role of stem cells in human uterine leiomyoma growth. PloS One. 2012;7:e36935.
60. Mas A, Cervelló I, Gil-Sanchis C, et al. Identification and characterization of the human leiomyoma side population as putative tumor-initiating cells. Fertil Steril. 2012;98:741-751.e6.
61. Conn PD, Crowley MW Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994;45:391-405.
62. Broekmans FJ, Hompes PG, Heitbrink MA, et al. Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: standard-dose therapy followed by reduced-dose therapy. Am J Obstet Gynecol. 1996;175:1208-1216. (Pubitemid 26398980)
63. Di Lieto A, De Rosa G, De Falco M, et al. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment. Hum Pathol. 2002;33:220-224. (Pubitemid 34298738)
64. Di Lieto A, De Falco M, Pollio F, et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig. 2005;12:123.
65. Chegini N, Luo X, Ding L, Ripley D. The expression of Smads and transforming growth factor β receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Mol Cell Endocrinol. 2003;209:9-16. (Pubitemid 37353078)
66. Chegini N, Verala J, Luo X, Xu J, Williams RS. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. J Soc Gynecol Investig. 2003;10:161.
67. Chegini N, Kornberg L. Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma. J Soc Gynecol Investig. 2003;10:21-26. (Pubitemid 36051094)
68. Wang Y, Matsuo H, Kurachi O, Maruo T. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells. Eur J Endocrinol. 2002;146:447.
69. Bifulco G, Miele C, Pellicano M, et al. Molecular mechanisms involved in GnRH analogue-related apoptosis for uterine leiomyomas. Mol Hum Reprod. 2004;10:43.
70. Friedman AJ, Rein MS, Harrison-Atlas D, Garfield JM, Doubilet PM. A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil Steril. 1989;52:728.
71. Andreyko JL, Blumenfeld Z, Marshall LA, Monroe SE, Hricak H, Jaffe RB. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging. Am J Obstet Gynecol. 1988;158:903.
72. Schlaff WD, Zerhouni EA, Huth JA, Chen J, Damewood MD, Rock JA. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obstet Gynecol. 1989;74:856.
73. Stovall TG, Muneyyirci-Delale O, Summitt RL Jr, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol. 1995;86: 65-71.
74. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG. 2002;109:1097-1108. (Pubitemid 35287078)
75. Vercellini P, Trespìdi L, Zaina B, Vicentini S, Stellato G, Crosignani PG. Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial. Fertil Steril. 2003;79:1390-1395. (Pubitemid 36687886)
76. Sitruk-Ware R, Inki P. The levonorgestrel intrauterine system: long-term contraception and therapeutic effects. Womens Health (Lond Engl). 2005;1:171-182.
77. Xu Q, Qiu L, Zhu L, Luo L, Xu C. Levonorgestrel inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Contraception. 2010;82:301-308.
78. Kriplani A, Awasthi D, Kulshrestha V, Agarwal N. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynaecol Obstet. 2012;116;35-38.
79. Gunes M, Ozdegirmenci O, Kayikcioglu F, Haberal A, Kaplan M. The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study. J Minim Invasive Gynecol. 2008;15:735-738.
80. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest. 2005;59:29-35. (Pubitemid 40082294)
81. Murat Naki M, Tekcan C, Ozcan N, Cebi M. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes. Fertil Steril. 2010;94:371-374.
82. Cadepond PF, Ulmann MD, Baulieu MD. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med. 1997;48: 129-156.
83. Stewart EA, Austin DJ, Jain P, Penglase MD, Nowak RA. RU486 suppresses prolactin production in explant cultures of leiomyoma and myometrium. Fertil Steril. 1996;65:1119-1124. (Pubitemid 26158626)
84. Xia L, Coon JS, Su E, et al. LAT1 regulates growth of uterine leiomyoma smooth muscle cells. Reprod Sci. 2010;17:791-797.
85. Luo X, Yin P, Reierstad S, et al. Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. J Clin Endocrinol Metab. 2009;94:4533-4539.
86. Yin P, Lin Z, Reierstad S, et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res. 2010;70:1722-1730.
87. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab. 1993;76:513.
88. Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril. 1995;64:187.
89. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Lowdose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101:243.
90. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006;108:1381.
91. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol. 2005;12:227-233. (Pubitemid 40800387)
92. Carbonell Esteve JL, Acosta R, Heredia B, Pérez Y, Castañeda MC, Hernández AV. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2008;112: 1029-1036.
93. Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Openlabel study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol. 2009;146:215-218.
94. Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol. 2009;49:77-83.
95. Morales AJ, Kettel LM, Murphy AA. Mifepristone: clinical application in general gynecology. Clin Obstet Gynecol. 1996;39:451-460. (Pubitemid 26143722)
96. DeManno D, Elger W, Garg R, et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids. 2003;68:1019-1032. (Pubitemid 37532427)
97. Wang J, Ohara N, Wang Z, et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFb3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod. 2006;21:1869-1877. (Pubitemid 44028263)
98. Sasaki H, Ohara N, Xu Q, et al. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab. 2007;92:616-623.
99. Chen W, Ohara N, Wang J, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab. 2006;91:1296-1304.
100. Xu Q, Ohara N, Liu J, et al. Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells. Am J Physiol Endocrinol Metab. 2007;293:E1002-E1011. (Pubitemid 47535831)
101. Morikawa A, Ohara N, Xu Q, et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod. 2008;23:944-951.
102. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril. 2007;87:1399-1412. (Pubitemid 46829155)
103. Wilkens J, Chwalisz K, Han C, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab. 2008;93:4664.
104. Blithe DL, Nieman LK, Blye RP, Stratton P, Passaro M. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids. 2003;68:1013-1017. (Pubitemid 37532426)
105. Gainer EE, Ulmann A. Pharmacologic properties of CDB (VA)-2914. Steroids. 2003;68:1005-1011.
106. Xu Q, Takekida S, Ohara N, et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly (adenosine 5′-diphosphate- ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab. 2005;90:953-961. (Pubitemid 40279221)
107. Yoshida S, Ohara N, Xu Q, et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med. 2010;28:260-273.
108. Xu Q, Ohara N, Chen W, et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod. 2006;21:2408-2416. (Pubitemid 44530620)
109. Xu Q, Ohara N, Liu J, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod. 2008;14:181-191. (Pubitemid 351404891)
110. Maruo T, Ohara N, Yoshida S, et al. Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system. Contraception. 2010;82:435-441.
111. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol. 2008;111:1129-1136. (Pubitemid 351620347)
112. Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril. 2011;95:767-772.e761-e762.
113. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409-420.
114. Donnez J, Tomaszewski J, Vázquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366:421-432.
115. Attardi BJ, Burgenson J, Hild SA, Reel JR. In vitro antiprogestational/ antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004;88:277-288. (Pubitemid 38553759)
116. Luo X, Yin P, Coon VJ, Cheng YH, Wiehle RD, Bulun SE. The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil Steril. 2010;93:2668-2673.
117. Roeder H, Jayes F, Feng L, Leppert PC. Cdb-4124 does not cause apoptosis in cultured fibroid cells. Reprod Sci. 2011;18:850-857.
118. Wiehle RD, Goldberg J, Brodniewicz T, Jarus-Dziedzic K, Jabiry-Zieniewicz Z. Effects of a new progesterone receptor modulator, CDB-4124, on fibroid size and uterine bleeding. US Obstet Gynecol. 2008;3:17-20.
119. Kaunitz AM. Aromatase inhibitor therapy for uterine bleeding in a postmenopausal woman with leiomyomata. Menopause. 2007;14:941-943. (Pubitemid 47517596)
120. Hilário SG, Bozzini N, Borsari R, Baracat EC. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertil Steril. 2009;91:240-243.
121. Shozu M, Murakami K, Segawa T, Kasai T, Inoue M. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertil Steril. 2003;79:628-631. (Pubitemid 36293465)
122. Gurates B, Parmaksiz C, Kilic G, Celik H, Kumru S, Simsek M. Treatment of symptomatic uterine leiomyoma with letrozole. Reprod Biomed Online. 2008;17:569-574.
123. Parsanezhad ME, Azmoon M, Alborzi S, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010;93:192-198.
124. Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Rajaratnam V, Al-Hendy A. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil Steril. 2010;94:1887-1893.
125. Zhang D, Al-Hendy M, Richard-Davis G, et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol. 2010;202:289.e1-289.e9.
126. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995;125:779-785.
127. Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab. 1998;83:219-223. (Pubitemid 28498339)
128. Catherino WH, Malik M, Driggers P, Chappel S, Segars J, Davis J. Novel, orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium. J Steroid Biochem Mol Biol. 2010;122:279-286.
129. Zhang C, Wen Z, Li J, et al. Inhibition of proliferation and transforming growth factor ss3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells. Chin Med J (Engl). 2008;121:166-171. (Pubitemid 351247892)
130. Singh NK, Chae HS, Hwang IH, et al. Transdifferentiation of porcine satellite cells to adipoblasts with ciglitizone. J Anim Sci. 2007;85:1126-1135. (Pubitemid 46693409)
131. Kim BY, Cho CH, Song DK, et al. Ciglitizone inhibits cell proliferation in human uterine leiomyoma via activation of store-operated Ca2+ channels. Am J Physiol Cell Physiol. 2005;288:C389-C395.
132. Nam DH, Ramachandran S, Song DK, et al. Growth inhibition and apoptosis induced in human leiomyoma cells by treatment with the PPAR γ ligand ciglitizone. Mol Hum Reprod. 2007;13:829-836. (Pubitemid 350131357)
133. Pines M, Vlodavsky I, Nagler A. Halofuginone: from veterinary use to human therapy. Drug Dev Res. 2000;50:371-378.
134. Grudzien MM, Low PS, Manning PC, Arredondo M, Belton RJ, Nowak RA. The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells. Fertil Steril. 2010;93:1290-1298.
135. Koda A, Kurashina Y, Nakazawa M. The inhibition mechanism of histamine release by N-(3, 4-dimethoxycinnamoyl) anthranilic acid. Int Arch Allergy Immunol. 1985;77:244-245. (Pubitemid 15027290)
136. Shioda H. A double-blind controlled trial of N-(3, 4-dimethoxycinnamoyl) anthranilic acid on children with bronchial asthma. N-5 Study Group in Children. Allergy. 1979;34:213-219. (Pubitemid 10237256)
137. Yamada H, Tajima S, Nishikawa T, Murad S, Pinnell SR. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem (Tokyo). 1994;116:892-897. (Pubitemid 24323674)
138. Suzawa H, Kikuchi S, Arai N, Koda A. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol. 1992;60:91.
139. Hiroi M, Onda M, Uchida E, Aimoto T. Anti-tumor effect of N-[3, 4-dimethoxycinnamoyl]-anthranilic acid (tranilast) on experimental pancreatic cancer. J Nippon Med Sch. 2002;69:224-234. (Pubitemid 34717634)
140. Chakrabarti R, Subramaniam V, Abdalla S, Jothy S, Prud'homme GJ. Tranilast inhibits the growth and metastasis of mammary carcinoma. Anticancer Drugs. 2009;20:334-345.
141. Shime H, Kariya M, Orii A, et al. Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21waf1 and p53. J Clin Endocrinol Metab. 2002;87:5610-5617. (Pubitemid 36034367)
142. Islam MS, Protic O, Stortoni P, et al. Antiproliferative effect of tranilast on human myometrial and leiomyoma cells. Biol Biomed Rep. 2012;2:321-327.
143. Boettger-Tong H, Shipley G, Hsu CJ, Stancel GM. Cultured human uterine smooth muscle cells are retinoid responsive. Proc Soc Exp Biol Med. 1997;215:59-65.
144. Tsibris JC, Porter KB, Jazayeri A, et al. Human uterine leiomyomata express higher levels of peroxisome proliferator-activated receptor γ, retinoid X receptor α, and all-trans retinoic acid than myometrium. Cancer Res. 1999;59:5737-5744.
145. Boettger-Tong HL, Stancel GM. Retinoic acid inhibits estrogeninduced uterine stromal and myometrial cell proliferation. Endocrinology. 1995;136:2975-2983.
146. Catherino WH, Malik M. Uterine leiomyomas express a molecular pattern that lowers retinoic acid exposure. Fertil Steril. 2007;87: 1388-1398. (Pubitemid 46829156)
147. Malik M, Webb J, Catherino WH. Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells. Clin Endocrinol (Oxf). 2008;69:462-470.
148. Ben-Sasson H, Ben-Meir A, Shushan A, et al. All-trans-retinoic acid mediates changes in PI3K and retinoic acid signaling proteins of leiomyomas. Fertil Steril. 2011;95:2080-2086.
149. Mason HR, Nowak RA, Morton CC, Castellot JJ Jr. Heparin inhibits the motility and proliferation of human myometrial and leiomyoma smooth muscle cells. Am J Pathol. 2003;162:1895-1904. (Pubitemid 36613047)
150. Park I, Park KK, Park JH, Chung WY. Isoliquiritigenin induces G2 and
151. Kim D, Ramachandran S, Baek S, et al. Induction of growth inhibition and apoptosis in human uterine leiomyoma cells by isoliquiritigenin. Reprod Sci. 2008;15:552-558. (Pubitemid 351875956)
152. Surh YJ. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: a short review. Food Chem Toxicol. 2002;40:1091-1097.
153. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23: 363-398. (Pubitemid 36361976)
154. Swarnakar S, Paul S. Curcumin arrests endometriosis by downregulation of matrix metalloproteinase-9 activity. Indian J Biochem Biophys. 2009;46:59-65.
155. Malik M, Britten J, Driggers P, Payson M, Segars JH, Catherino WH. Curcumin, a nutritional supplement with antineoplastic activity, selectively inhibits leiomyoma growth. Fertil Steril. 2007;88:S217.
156. Tsuiji K, Takeda T, Li B, et al. Inhibitory effect of curcumin on uterine leiomyoma cell proliferation. Gynecol Endocrinol. 2011;27:512-517.
157. Bläuer M, Rovio PH, Ylikomi T, Heinonen PK. Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro. Fertil Steril. 2009;91:1919-1925.
158. Sharan C, Halder SK, Thota C, Jaleel T, Nair S, Al-Hendy A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O- methyltransferase. Fertil Steril. 2011;95:247-253.
159. Halder SK, Goodwin JS, Al-Hendy A. 1,25-Dihydroxyvitamin D reduces TGF-β3-Induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2011;96: E754-E762.
160. Halder SK, Sharan C, Al-Hendy A. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod. 2012;86:116.
161. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995;267:1782-1788.
162. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther. 1999;82:231-239. (Pubitemid 29255918)
163. Shushan A, Rojansky N, Laufer N, et al. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum Reprod. 2004;19:1957-1967. (Pubitemid 39236459)
164. Shushan A, Ben-Bassat H, Mishani E, Laufer N, Klein BY, Rojansky N. Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertil Steril. 2007;87:127-135. (Pubitemid 46013862)
165. Laping NJ. Therapeutic uses of smad protein inhibitors: selective inhibition of specific TGF-β activities. IDrugs. 1999;2:907-914. (Pubitemid 29423412)
166. Laping NJ, Everitt JI, Frazier KS, et al. Tumor-specific efficacy of transforming growth factor-β RI inhibition in Eker rats. Clin Cancer Res. 2007;13:3087-3099. (Pubitemid 46849586)